D&D Interactive Teams Up Against TB

D&D Interactive unveils new, state-of-the-art, website for Oxford Immunotec - a mediacal diagnostic company that recently unveiled a new TB blood test.

Philadelphia, PA, March 26, 2009 --(PR.com)-- D&D Interactive unveils new, state-of-the-art, website for Oxford Immunotec which can be viewed at www.oxfordimmunotec.com. Their new FDA approved tuberculosis blood test, T-SPOT.TB, proven to be more accurate and effective than the traditional TB skin tests (TST), is the first of many products Oxford Immunotec hopes to promote via their new website.

With International Headquarters in London, England and North American Headquarters in Boston, MA, Oxford Immunotec needed to carefully communicate their message of tuberculosis education and proper testing, appropriately to healthcare professionals, patients, and the media outlets in multiple continents.

D&D Interactive was able to accomplish this task by strategically designing and constructing a highly sophisticated, dual-sided website that allows Oxford’s staff to add and edit content that is unique to each audience. In addition, tactics for search engine optimization were executed to aid in their product marketing efforts.

“This was a real challenge that required an enterprise-level website,” reported D&D President, David Sonn. “We are proud to have armed our client with such a powerful online tool.”

About D&D Interactive:
D&D Interactive, Inc., is a responsive online solutions agency, specializing in interactive marketing and website development and optimization. D&D also offers services in design, branding, print, production, and promotions. Founded in 1996 and based in Bala Cynwyd, PA, clients include AstraZeneca, Philadelphia Sports Congress, the United Way of Southeastern Pennsylvania, Arrow Exterminators, Unique Indoor Comfort, and GlaxoSmithKline. For more information, please visit www.ddii.com.

About Oxford Immunotec
Oxford Immunotec, the T cell measurement company, is headquartered near Marlborough, MA and Oxford, UK. The Company develops and sells clinical diagnostic products based on its patented T-SPOT technology, the first regulatory approved method for directly quantifying antigen-specific T cells.

T-SPOT is a simple and extremely accurate method of studying a person’s cellular immune response to infection and can be applied to diagnose and monitor any major disease driven by a T cell response. For more information please visit www.oxfordimmunotec.com.

D&D Interactive, Inc.
Dana Weber